Company Description
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.
Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases.
In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn’s disease and ulcerative colitis.
Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases.
The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019.
Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 8, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 96 |
| CEO | Warner Biddle |
Contact Details
Address: 5980 Horton Street, Suite 550 Emeryville, California 94608 United States | |
| Phone | (510) 925-2492 |
| Website | kyvernatx.com |
Stock Details
| Ticker Symbol | KYTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $22.00 |
| CIK Code | 0001994702 |
| ISIN Number | US5019761049 |
| Employer ID | 83-1365441 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Warner Biddle | Chief Executive Officer and Director |
| Karen Walker | Chief Technology Officer |
| Ryan Jones M.B.A. | Chief Financial Officer |
| Dr. Tom Van Blarcom Ph.D. | Senior Vice President and Head of Research |
| Cara Bauer | Chief Human Resources Officer |
| Dr. Dominic Borie M.D., Ph.D. | President of Research and Development |
| Devin Murray | Senior Vice President of Partnerships and Alliances |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 21, 2024 | 8-K | Current Report |
| Oct 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 16, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | 8-K | Current Report |